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Abstract: Neutralising antibodies (NAbs) represent the real source of protection against SARS-CoV-
2 infections by preventing the virus from entering target cells. The gold standard in the detection of 
these antibodies is the plaque reduction neutralization test (PRNT). As these experiments must be 
done in a very secure environment, other techniques based on pseudoviruses: pseudovirus neutral-
ization test (pVNT) or surrogate virus neutralization test (sVNT) have been developed. Binding 
assays, on the other hand, measure total antibodies or IgG, IgM, and IgA directed against one 
epitope of the SARS-CoV-2, independently of their neutralizing capacity. The aim of this study is to 
compare the performance of six commercial binding assays to the pVNT and sVNT. In this study, 
we used blood samples from a cohort of 62 RT-PCR confirmed COVID-19 patients. Based on the 
results of the neutralizing assays, adapted cut-offs for the binding assays were calculated. The use 
of these adapted cut-offs does not permit to improve the accuracy of the serological assays and we 
did not find an adapted cut-off able to improve the capacity of these tests to detect NAbs. For a part 
of the population, a longitudinal follow-up with at least two samples for the same patient was per-
formed. From day 14 to day 291, more than 75% of the samples were positive for NAbs (n = 87/110, 
79.1%). Interestingly, 6 months post symptoms onset, the majority of the samples (N = 44/52, 84.6%) 
were still positive for NAbs. This is in sharp contrast with the results we obtained 6 months post-
vaccination in our cohort of healthcare workers who have received the two-dose regimens of 
BNT162b2. In this cohort of vaccinated subjects, 43% (n = 25/58) of the participants no longer exhibit 
NAbs activity 180 days after the administration of the first dose of BNT162b2. 
Keywords: COVID-19; SARS-CoV-2; neutralizing antibody 
 
1. Introduction 
The detection of antibodies directed against the spike protein (S protein), the recep-
tor-binding domain (RBD), or the nucleocapsid (N) in the serum or plasma of convales-
cent patients allows monitoring of the development of adaptive immunity after SARS-
CoV-2 infection or vaccination [1–3]. Following infection or vaccination, numerous anti-
bodies are produced targeting different epitopes of the virus or the spike protein. Never-
theless, not all these antibodies are able to efficiently neutralize the virus since they can 
bind an epitope which is not essential for the virus entry into the cell. Therefore, the de-
tection of neutralizing antibodies (NAbs) is of particular importance because these are the 
antibodies that can prevent the binding of the RBD of the S protein to the angiotensin-
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converting enzyme 2 (ACE2) receptor present at the surface of human cells, preventing 
the entry of the virus into the host cells [4]. 
In their recent study, Montesinos et al. presented serological data obtained from a 
series of six binding assays and compared their clinical performances against a plaque 
reduction neutralization test (PRNT) at a 1/80 titer [5]. They concluded that “VIDAS IgG 
and Euroimmun QuantiVac IgG showed a better ability to detect NAbs” with an area un-
der the ROC curve of 0.96 (95% CI: 0.93–0.98) and 0.95 (95% CI: 0.92–0.98), respectively. 
According to the authors, the Roche assays, i.e., targeting the nucleocapsid or the spike 
protein, were less able to detect neutralizing antibodies (NAbs) with AUC of 0.87 (95% CI: 
0.81–0.92) and 0.88 (95% CI: 0.82–0.93), respectively. They also reported a significant de-
crease in NAbs in 16.9% (11/65) subjects at the 6 months follow-up. Using their data, 33.3% 
(21/63) of the subjects lost their positivity with the VIDAS IgG and 27.7% (18/65) with the 
Euroimmun QuantiVac IgG. Having these data in mind, it is difficult to definitely con-
clude that these tests showed a better ability to detect NAbs than the other tests evaluated 
in this study [5]. In addition, our group and others previously showed that the positivity 
threshold reported in the instructions for using the Roche Elecsys® anti-SARS-CoV-2 spike 
is not a threshold for correlating with neutralization [6–11]. It was demonstrated that 
higher antibody titers are needed to correlate with seroneutralization although this is sub-
ject to the diversity of antibody response among individuals [7,11]. This has also been 
observed in vaccinated subjects [6]. 
2. Materials and Methods 
To complement the data from Montesinos et al., we would like to share our experi-
ence on a similar cohort of SARS-CoV-2 infected individuals and report the evolution of 
the positivity rate of the different serological tests over time versus a validated pseudo-
virus neutralization test (pVNT). In a cohort of 62 RT-PCR confirmed COVID-19 patients, 
114 samples were collected from day 1 to day 296 after symptom onset; the average age 
of the population was 55.66 years (range 24–95), the gender was 50% male and 50% female, 
and the hospitalization rate was 25.80%. 
In this cohort, we assessed six commercial binding assays, namely: the Roche (Basel, 
Switzerland) nucleocapsid (NCP) total antibody assay (positivity cut-off = 1.0 cut-off in-
dex (COI)), the Roche RBD total antibody assay (positivity cut-off = 0.8 U/mL), the Di-
aSorin (Saluggia, Italy) S1/S2 IgG assay (positivity cut-off = 15 AU/mL), the Ortho (Raritan, 
NJ, USA) S1 IgG assay (positivity cut-off = 1.0 S/V (sample signal/threshold value)), the 
Ortho S1 total antibody assay (positivity cut-off = 1.0 S/V), and the Phadia (Portage, MI, 
USA) S1 IgG assay (positivity cut-off = 0.7 U/L) and two neutralizing techniques, a surro-
gate virus neutralization test (sVNT) (positivity cut-off = 10 AU/mL) and a pVNT (posi-
tivity cut-off = 1/20 dilution factor of serum sample), as described previously [8,12–14]. All 
of these samples were collected before the SARS-CoV-2 vaccination campaign, which 
started in Belgium in January 2021. Descriptive statistics were used to analyze the data. 
ROC curves were performed to define cut-off values with the best specificity and sensi-
tivity for each serological test. Sensitivity, specificity, positive and negative predictive val-
ues, as well as the accuracy, were calculated for the cut-offs provided by the manufacturer 
as well as for the adapted cut-offs obtained with the ROC curves as determined by 
Youden’s index. A simple linear regression and Pearson correlations were computed to 
assess the potential association between NAb and antibody titers. Inter-rater agreements 
were also determined. Data analysis was performed using GraphPad Prism® software 
(version 9.1.0, San Diego, CA, USA) and MedCalc® Software Ltd. (Diagnostic test evalua-
tion calculator, Version 20.014. Available online: https://www.medcalc.org/calc/diagnos-
tic_test.php accessed 12 October 2021). 
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3. Results and Discussion 
Using the cut-off provided by the manufacturers, the sensitivity did not statistically 
differ between the different serological assays investigated in this study (Table 1). The 
specificity was below 50.0% for all assays meaning that these assays generated many false-
positive results for the detection of NAbs. The accuracy for detecting NAbs was, in gen-
eral, below 90% and stayed around 80% for all assays. The use of adapted cut-offs does 
not permit to improvement in the accuracy of these serological assays. It means that we 
needed to deal with a loss of sensitivity or specificity in order to increase to other param-
eters (i.e., specificity or sensitivity and accuracy). However, there was no real possibility 
to improve the capacity of these tests to detect NAbs by adapting the cut-offs (Tables 1 
and 2). 
Table 1. Summary table of the analytical sensitivity, specificity, positive predictive value, negative predictive value, and 
accuracy of the six serological assays investigated in this study and sVNT technique in comparison with the pVNT.  Re-
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Table 2. Summary of discrepancies between pVNT versus serological assays and sVNT in samples from patients with 
COVID-19. The total number of pVNT negative and positive samples were 25 and 89, respectively. Discordant results 






(>20 = POS) 
sVNT 
AU/mL 
(>10 = POS) 
Roche RBD 
Total Ab U/mL 
(≥0.8 = POS) 
Roche NCP 
Total Ab U/mL 
(≥1.0 = POS) 
Ortho S1 Total 
Ab S/V 
(≥1.0 = POS) 
Ortho S1 IgG 
S/V 
(≥1.0 = POS) 
Diasorin S1+S2 
IgG AU/mL 
(≥15 = POS) 
Phadia S1 IgG 
U/mL 
(>0.7 = POS) 
 False positive | PVNT Negative/Serological Positive 
1 10.00 16.24 1.13 1.50 1.83 0.24 19.10 1.20 
18 19.60 9.12 0.4 0.20 1.32 0.05 27.60 0.70 
29 10.46 10.50 174.00 33.20 255.00 11.50 78.80 73.00 
38 10.09 7.49 0.40 5.06 0.31 0.01 3.80 0.70 
46 10.00 8.66 0.40 24.50 1.87 0.15 7.00 5.60 
47 19.54 50.36 127.00 32.30 138.00 9.61 58.00 28.00 
49 14.24 13.04 57.30 19.10 60.30 9.64 47.00 24.00 
75 10.00 6.19 322.00 37.20 271.00 12.50 86.80 250.00 
76 13.86 12.20 153.00 22.60 126.00 12.30 73.10 58.00 
109 18.51 22.69 2219.00 114.00 552.00 19.00 311.00 186.00 
122 13.82 9.53 0.61 20.80 4.57 0.20 11.00 9.00 
129 19.06 8.61 2.44 4.75 47.90 2.75 6.30 7.80 
169 19.34 7.59 3.36 15.00 18.90 0.19 3.80 1.90 
171 10.00 3.59 42.30 15.50 109.00 7.37 62.30 36.00 
197 10.00 8.69 476.00 48.30 136.00 17.30 141.00 790.00 
197 17.51 8.59 41.60 26.40 164.00 7.20 32.10 31.00 
230 10.00 10.05 4.80 2.38 12.10 5.05 11.10 11.00 
233 10.00 3.63 0.75 14.34 0.54 0.53 11.53 8.71 
236 10.00 10.50 0.40 11.30 7.77 0.15 9.60 9.90 
239 19.05 9.09 31.90 3.20 60.10 9.93 48.60 34.00 
274 10.00 9.58 191.00 9.57 120.00 14.10 132.00 1950.00 
296 12.52 9.61 5.33 9.20 12.70 5.70 43.80 18.00 
False Posi-
tive 














 False Negative | PVNT Positive/Serological Negative 
12 34.87 10.52 27.50 3.95 39.30 2.61 14.20 5.80 
21 52.36 47.69 11.70 57.30 22.60 6.08 12.70 19.00 
54 289.70 50.55 2.70 3.36 4.81 0.07 20.90 0.70 
72 81.25 8.40 4.52 13.60 10.10 0.24 7.50 3.80 
101 173.09 52.61 1.61 16.00 2.41 0.86 7.00 3.00 
107 25.90 75.66 0.40 3.94 4.36 0.20 8.12 14.00 
108 63.18 40.70 18.40 27.80 33.80 0.57 7.10 3.20 
175 36.67 11.60 0.40 0.07 0.06 0.01 3.80 0.70 
183 57.18 20.90 0.81 0.46 1.34 0.33 6.00 10.00 
229 219.43 17.21 65.90 90.40 1.55 0.17 46.80 27.00 
229 46.52 15.90 3.60 28.70 10.90 3.60 9.80 11.00 
235 48.41 26.68 7.76 95.90 13.30 3.55 11.70 11.00 
237 76.84 30.44 12.10 44.70 23.30 4.92 10.00 12.00 
240 20.00 4.69 142.00 37.60 116.00 13.70 103.00 204.00 
259 37.48 29.97 1.26 5.09 2.38 0.14 24.40 1.00 
False nega-
tive 
































It is also interesting to analyze in more detail the samples that showed discordant results 
between pVNT and serological assays (Figure 1 and Table 2). In general, serological assays 
targeting total antibodies, i.e., Roche RBD, Roche NCP, and Ortho S1 total antibodies gener-
ated less false-negative results. This meant that also measuring both IgA and IgM permitted 
to better evaluate the neutralizing capacity of the serum than just targeting IgG. In general, the 
rate of false-negative was around 3% for assays targeting total antibodies while it was around 
10% for assays specific towards IgG except for the Phadia S1 IgG, which showed a false 
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negative’s rate of 2.2%. Nevertheless, this is at the detriment of a higher false-positive rate, 
which may be up to 84.0% for the Roche NCP total antibody assay. On the other hand, assays 
specific for IgG do not show very good performance either since their false positive rate was 
around 50 to 80%. These results were also confirmed by the ROC curves analyses (Figure 2). 
Therefore, binding immunoassays which showed the best agreement with NAbs as deter-
mined by a pVNT method are the Roche total RBD, Roche total NCP, and the Ortho S1 total 
antibodies. Nevertheless, all of these binding immunoassays demonstrated poor correlation 
with results obtained in pVNT (Figure S1). These results are confirmed by the ROC curves 
analyses (Figure 2). 
 
Figure 1. Evolution of NAbs titer in pVNT (A) and sVNT (B) as a function of days post symptoms 
onset. Green squared and purple dots are concordant results. Squares framed in red are those for 
which there is a discordant result between pVNT result and at least one of the six non-neutralizing 
immunoassays. Dots circled in orange are those for which there is a discordant result between sVNT 
and at least one of the six non-neutralizing immunoassays. Dots circled in red are those for which 
only sVNT was discordant. Red dots are those for which sVNT is discordant from pVNT. The details 
of these discrepancies are reported in Table 2. 
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It is interesting to compare the results obtained with the sVNT which targets NAbs 
with those obtained with the pVNT technique (Figure 1). This test showed the best corre-
lation with the pVNT technique, i.e., 32.0% of false-positive and 2.2% of false negative. 
The majority of the false-positive results (6/8) presented in Table 2 are close to the cut-off 
of the sVNT technique ranging from 10.05 AU/mL to 16.24 AU/mL. Based on the ROC 
curve analysis (Figure 2), the adapted cut-off of the sVNT increases from 10 AU/mL to 
16.6 AU/mL. This new cut-off increases the specificity from 65.2% to 92.0% without sig-
nificantly impacting the other computed parameters. This differs from other serological 
tests where an adapted cut-off increases specificity while negatively impacting other pa-
rameters. The correlation between the pVNT results and the sVNT results is better than 
the other tests, but the data remains very heterogeneous (Figure S1). 
 
Figure 2. Roc curve analyses of all serological tests in this study and sVNT technique in comparison 
with pVNT based on the manufacturer’s cut-offs. 
This study also permits the evaluation of the dynamic of NAbs production after symp-
toms onset in patients suffering from COVID-19. For a part of the population, a longitudinal 











Phadia S1 IgG | AUC: 0.570 (95% CI: 0.425 - 0.715)
Ortho S1 total Ab | AUC: 0.748 (95% CI: 0.646 - 0.851)
Ortho S1 IgG | AUC: 0.653 (95% CI: 0.522 - 0.783)
Diasorin S1+ S2 IgG | AUC: 0.675 (95% CI: 0.550 - 0.800)
Roche NCP total Ab | AUC: 0.806 (95% CI: 0.719 - 0.894)
sVNT NAbs | AUC: 0.944 (95% CI: 0.894 - 0.994)




Figure 3. (A) Kinetics of NAbs since the symptom onset in non-hospitalized and hospitalized pa-
tients. Blue plain lines represent non-hospitalized patients and red plain lines represent hospitalized 
patients. Samples obtained at different times for the same patient are connected by dotted lines. (B) 
Kinetics of NAbs since the day of first dose vaccination in seronegative and seropositive individuals. 
Blue plain lines represent seronegative individuals and red plain lines represent seronegative indi-
viduals. Samples obtained at different times for the same individual are connected by dotted lines. 
From day 14 to day 291, more than 75% of the samples were positive for NAbs (n = 
87/110, 79.1%). Interestingly, 6 months post symptoms onset, the majority of the samples 
(N = 44/52, 84.6%) were still positive for NAbs. 
This is in sharp contrast with the results we obtained 6 months post-vaccination in 
our cohort of healthcare workers who received the two-dose regimens of BNT162b2 [6]. 
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In this cohort of vaccinated subjects, 43% (n = 25/58) of the participants no longer 
exhibit NAbs activity 180 days after the administration of the first dose of BNT162b2 [6]. 
This is a very interesting observation since even those who were seropositive at baseline, 
i.e., a documented previous infection to SARS-CoV-2, seemed to lose their neutralizing 
capacity (n = 7/18, 39%) [6]. (Figure 3B) The comparison between the results obtained in 
COVID-19 patients and those obtained in vaccinated individuals with or without previous 
COVID-19 infection is presented in Figure 4. 
 
Figure 4. Comparison of NAbs titers between COVID-19 patients, seropositive vaccinated individuals, 
and seronegative vaccinated individuals at three different timeframes. The median is presented on top 
of each timeframe for each population. Bars represent the mean and standard error or mean. 
C. Jeewandara et al. also pointed out a relationship between the development of 
NAbs and the time of exposure to the virus. In their study, patients with prolonged expo-
sure to SARS-CoV-2 had a higher NAbs titer than patients who cleared the virus ear-
lier.[15] Such differential response could be explained by a longer exposure to the anti-
gen(s) during the course of COVID-19 disease compared to vaccination, where it is sup-
posed that the antigen is rapidly cleared from the body. These results deserve further in-
vestigations to better understand the difference in the dynamic of antibody production 
after COVID-19 disease and vaccination. 
Supplementary Materials: The following is available online at www.mdpi.com/arti-
cle/10.3390/v13112329/s1, Figure S1: Head-to-head comparison of the pVNT to 6 non-neutralizing immu-
noassays and the sVNT technique. Black dotted lines correspond to the positivity threshold of each assay. 
Author Contributions: Among the authors, C.G., J.D., and J.-M.D. were responsible for the first 
draft, C.G., V.M., and J.F. were responsible for the analyses. C.G. and J.D. were responsible for the 
data analyses. J.D. was responsible for the fundraising. All authors have read and agreed to the 
published version of the manuscript. 
Funding: No funding. 
Institutional Review Board Statement: The study protocol was in accordance with the Declaration 
of Helsinki and was approved by the Medical Ethical Committee of Saint-Luc Bouge (Bouge, Bel-
gium, approval number B0392020000005). 
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